10.18

3.04% 0.30

After Hours: 10.18

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $10.18, with a volume of 2.24M. It is up +3.04% in the last 24 hours and up +5.38% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$9.88

Open:

$9.65

24h Volume:

2.24M

Relative Volume:

2.67

Market Cap:

$519.70M

Revenue:

$85.21M

Net Income/Loss:

$-140.11M

P/E Ratio:

-4.0484

EPS:

-2.5146

Net Cash Flow:

$-109.62M

1W Performance:

+13.36%

1M Performance:

+5.38%

6M Performance:

+21.33%

1Y Performance:

+181.99%

1-Day Range:

$9.64

$10.71

1-Week Range:

$8.59

$10.71

52-Week Range:

$2.235

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

196

Twitter

Next Earnings Date

2026-03-20

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	10.18	504.39M	85.21M	-140.11M	-109.62M	-2.5146
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

09:02 AM

HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Mar 22, 2026

Mar 21, 2026

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail

Mar 21, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen - MarketBeat

Mar 21, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to “Hold” at Wall Street Zen - Defense World

Mar 21, 2026

Mar 20, 2026

4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail

Mar 20, 2026

4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 20, 2026

4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at Chardan Capital - Defense World

Mar 20, 2026

Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies - TipRanks

Mar 20, 2026

Mar 19, 2026

4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st

Mar 19, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada - MarketBeat

Mar 19, 2026

4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus

Mar 19, 2026

Chardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat

Mar 19, 2026

RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com

Mar 19, 2026

4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart

Mar 19, 2026

Mar 18, 2026

4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart

Mar 18, 2026